|
May 12
|
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
|
|
May 10
|
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript
|
|
May 10
|
Mersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed Analysis
|
|
May 9
|
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 9
|
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
|
|
May 2
|
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
|
|
Apr 5
|
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
|
|
Jan 2
|
The past three years for Mersana Therapeutics (NASDAQ:MRSN) investors has not been profitable
|
|
Aug 8
|
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 8
|
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
|
|
Aug 4
|
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jun 22
|
Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More
|
|
Apr 26
|
Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting
|